Introduction
It is now generally accepted that malignant cells possess specific antigenic determinants which appear as new antigenic moieties on cells transformed by viruses (St/ich et al., 1964; Pasternak, 1967; Steeves, 1968) or chemical carcinogens (Foley, 1953; Prehn and Main, 1957; Klein et al., 1960) . In spite of painstaking efforts to regulate the immune defense system of the tumor-bearing host (TBH) so as to increase the host's resistance to tumor, there is as yet no consistent method for prevention of tumor growth. Among the immunological approaches used one may cite the specific, active (Math~ et al., 1969; Nadler and Moore, 1970; Morton et al., 1970) and passive (Woodruff and Nolan, 1963; Symes et al., 1968; Moore and Gerner, 1970; Curtis, 1971; Alexander and Delorme, 1971) 
immunization procedures and the nonspecific procedures, such as immunization with
Reprint requests should be addressed to: A. H. Sehon BCG (Bast, 1974) or Corynebacterium parvum (Woodruff and Boak, 1966; Currie and Bagshawe, 1970) , considered to result in the elevation of the total immune reactivity of the host. The failure to induce an effective antitumor immune response in TBH may be attributed to a 'negative' regulatory mechanism due to suppressor cells and their soluble factors (Fujimoto et al., 1975 (Fujimoto et al., , 1976a Greene et al., 1977) which underlies the immune response in TBH and/or to 'blocking' of the cytotoxic cell-mediated response by circulating tumor antigens (TA) or antibody-antigen complexes (Baldwin et al., 1973; Currie, 1973; Hellstr6m and Hellstr6m, 1975) .
In the hope of circumventing these unresolved tumor-host relationships, studies were devised in this laboratory with a view to evaluating the possibility of developing two model systems for the destruction of tumors by immunological mechanisms involving either (1) an indirect cell-mediated reaction (Berczi et al., 1972) or (2) the use of conjugates of cytotoxic drugs with antibodies directed to antigenic determinants of tissue constituents which are present in the tumor foci, rather than to TA per se because of the difficulty in inducing anti-TA antibodies in adequate amounts. In recent studies in this laboratory, advantage was taken of the observation that fibrin is deposited in a variety of animal and human solid tumors (O'Meara, 1958; Day et al., 1959; Spar et al., 1964) suggesting that fibrin may be an important supporting lattice for tumor growth by providing a source of protein and a barrier for free circulation of tissue fluids in the tumor foci, thereby impeding the contact of immunocompetent cells with tumor cells. The first model described in the accompanying paper (Lee et al., 1978a) consists in essence of two stages: (a) the injection of xenogeneic antibodies specific for the unique antigenic determinants of fibrin, and (b) the transfer of lymphocytes from donors syngeneic to TBH in whom a state of cell-mediated immunity to immunoglobulins isotypic with the antifibrin antibodies has been induced.
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Thus, it was visualized that (a) the antifibrin antibodies would become fixed to the fibrin matrix enmeshing the tumor, and (b) the sensitized lymphocytes would home onto the antibody-coated fibrin lattice and would liberate, on contact with these antibodies, factors leading locally to a cytopathic inflammatory response, which would culminate in the destruction of the t u m o r nodule. The second model, described in a separate paper (Lee et al., 1978b) , consists in administering conjugates of goat anti-guinea pig fibrin antibodies with d a u n o m y c i n , a potent toxic drug used in cancer chemotherapy.
In this article are described the procedures used for the preparation of pure antibodies specific for the unique antigenic determinants of guinea pig fibrin and for the in vivo localization of these antibodies in the methylcholanthrene induced sarcoma (MC-D) transplantable in strain 13 guinea pigs, which grows within a fibrin lattice. The preliminary results of this study were c o m m u n icated earlier (Fujimoto et al., 1973) , but the present paper was n o t submitted for publication in anticipation of completing the two studies described in the succeeding papers (Lee et al., 1978a, b) , which demonstrate the usefulness of antifibrin antibodies for developing immunotherapeutic strategies for the destruction of tumors growing within a fibrin mesh. More recently, evidence has been presented (Schlager and Dray, 1975 ) that the subcutaneous injection of antibodies to the fibrin fragment E, after the intradermal implantation of a uniformly lethal dose of line-10 t u m o r cells in strain 2 guinea pigs, resulted in complete regression of the t u m o r and the animals so treated became resistant to subsequent tumor challenge.
Materials and Methods
Tumor. The MC-D sarcoma, originally donated by Dr. H. F. Oettgen of the Sloan-Kettering Institute in New York, was used in this study. The tumor was maintained by subcutaneous implantation into adult, male and female inbred Sewall Wright strain 13 guinea pigs. The presence of fibrin in the tumor was demonstrated histologically by staining with phosphotungstic acid-hematoxylin.
Guinea Pig Fibrinogen and Fibrin. Guinea pig fibrinogen and fibrin were prepared according to the method of Day et al. (1959) . Guinea pig fibrinogen was precipitated from a volume of 150-200 ml of fresh plasma (with 0.38% sodium citrate) by two volumes of a NaC1 solution (277.5 g NaC1/1). The precipitate was dissolved in distilled water and was reprecipitated with the NaC1 solution. The fibrinogen was finally dissolved in phosphate buffered saline (PBS), pH 7.2, and was dialyzed extensively against the same buffer.
For conversion of fibrinogen to fibrin, the dialyzed fibrinogen solution from 150 ml of plasma was diluted to 11 with PBS. To this solution was added 5 ml of 0.2 M CaC12 solution and 1,000 NIH units of bovine thrombin (Sigma Chemical Co., St. Louis, Missouri). The fibrin was wound around a glass rod as it was being formed and was dispersed into a suspension of fine particles in PBS with a glass homogenizer. These particles were washed several times with PBS al.: Use of Antifibrin Antibodies for Destruction of Tumor Cells. I until the optical density of the supernatant was less than 0.01 at 280 px and the preparation was stored at -2 0 ° C. Anti-Guinea Pig Fibrin Serum. For the production of anti-guinea pig fibrin serum, goats were rendered tolerant to fibrinogen by injection of 10 mg N of aggregate-free guinea fibrinogen prepared by centrifugation at 100,000 g for 1 h. The goats were then immunized by four intramuscular injections of 2 mg N of purified guinea pig fibrin suspension in PBS, emulsified with the same volume of Freund's complete adjuvant (FCA), at 2-week intervals. The goats were bled and the antisera were pooled, heated at 56 ° C for 30 min to inactivate complement and stored at -2 0 ° C. Anti-guinea pig fibrin serum was also produced in rabbits by the same procedure.
Production of

Isolation of Specific Anti-Guinea Pig Fibrin Antibodies (A GFA).
Before isolation of specific antibodies to guinea pig fibrin, the pooled goat antiserum was first absorbed (1) with normal guinea pig serum to remove antibodies to constituents of the serum which bad been occluded in the fibrin used for immunization of the goats, and (2) with fibrinogen to remove antibodies directed against antigenic determinants shared by both fibrin and fibrinogen. The completeness of these absorption steps was further confirmed by the standard precipitin test, and by immunoelectrophoresis.
For the final isolation of antibodies to only the unique antigenic determinants of fibrin, appropriate immunosorbents were used. First, the antibodies were adsorbed onto fibrin. For this purpose the suspension of guinea pig fibrin was washed once with glycine-HC1 buffer, pH 2.8, and then with PBS several times. The washed purified fibrin (20 mg N) was mixed with 100 ml of the above antibody preparation. The suspension of fibrin-antibody complexes was incubated for 1 h at room temperature and then at 4 ° C overnight with continuous gentle shaking. It was then washed with PBS until the optical density of the supernatant was less than 0.01 at 280 ~. Antifibrin antibodies were then eluted off the fibrin immunosorbent with glycine-HC1 buffer, pH 2.8, at 4 ° C. Immediately after elution, the antibody solution was neutralized by adding NaOH dropwise and dialyzed against PBS, pH 7.2. Furthermore, to exclude the possibility that the purified antibodies might still have contained antibodies capable of crossreacting with fibrinogen, the preparation was passed again through an immunosorbent column consisting of purified guinea pig fibrinogen (15 rag) coupled to CNBr activated Sepharose 4B (20 ml) (Pharmacia Fine Chemicals, Uppsaia, Sweden), according to the method of Axtn et al. (1967) .
In general, the nitrogen content of protein samples was established by the method of Koch and McMeekin (1924) .
Preparation of Rabbit Anti-Guinea Pig Fibrinogen Antibodies.
For production of anti-guinea pig fibrinogen antibodies, rabbits were given, at 1 week intervals, two series of subcutaneous injections consisting of 1 mg N of purified guinea pig fibrinogen emulsified in 1 ml of FCA; the fibrinogen had been isolated as described previously. The rabbits were bled 1 week and 2 weeks after the second injection. The antisera were pooled and heated at 56 ° C for 30 min. The IgG fraction of this pool was isolated by chromatography on a Sephadex G-200 column (2.6 x 100 cm), which had been equilibrated with 0.005 M borate buffered saline, pH 8.0, and concentrated by negative pressure dialysis after overnight dialysis against PBS.
~31[-labelled AGFA. One milligram of AGFA was reacted with 500 ~Ci of 131I at 4 ° C using the chloramine T method of McConahey and Dixon (1966) with slight modifications. After labelling, the antibodies were passed through a Sephadex G-25 column to remove any free radioactive iodine.
To eliminate any AGFA which may have been inactivated during radio-iodination, the labelled antibodies were repurified by treating them with the fibrin immunosorbent and the mI-labelled anti-bodies were eluted with glycine-HC1 buffer, pH 2.8. After neutralization with 1.0 N NaOH, the 131I-labelled antibody preparation was extensively dialyzed against PBS before use.
In Vitro Binding of AGFA with Fibrin and Tumor Tissue Pellet (TTP).
Constant amounts (0.1 ~g N) of ~3~I-labelled AGFA were added to a series of test tubes containing serially diluted purified guinea pig fibrin or a suspension of TTP, prepared by homogenization of the tumor and extensive washing with PBS until the supernatant had an OD less than 0.02 at 280 ~. The TTP was used either when freshly prepared, or after lyophilization. As a control, ~31I-labelled normal goat IgG was used instead of AGFA in all tests. After 24 h incubation on a shaker at 4 ° C, the residue in each test tube was washed five times with cold PI3S, and the bound radioactivity determined in a well-type ?;-ray counter (Nuclear, Chicago).
Double Precipitation Test for the Specificity of A GFA.
To ascertain that the AGFA preparation was indeed free of antibodies to fibrinogen, which may have been present in too low a concentration for detection by the standard precipitin test, a double antibody precipitation procedure was resorted to. For this purpose constant amounts of 131I-labelled guinea pig flbrinogen (0.1 vg N) were added to three sets of test tubes containing serial dilution of (a) rabbit anti-guinea pig fibrinogen antibodies (positive control); (b) the goat AGFA preparation; (c) normal goat IgG (negative controD. After thorough mixing, the test tubes were maintained at 4 ° C for 30 rnin and subsequently optimal amounts of sheep anti-rabbit IgG serum were added to the first set of tubes and of rabbit anti-goat IgG serum to the other two sets. The optimal amounts of these antisera (determined previously by the precipitin test) were chosen so as to lead to complete precipitation of the rabbit and goat IgG present in the corresponding test tubes. After mixing, the test tubes were kept on a shaker at 4 ° C for 24 h. The precipitates were centrifuged down and washed five times with cold PBS and the residual radioactivity determined.
Preparation of Fluorescent Antibodies. In vivo localization of goat antifibrin antibody within the tumor tissue was demonstrated by the indirect fluorescent antibody technique. The IgG fraction of rabbit anti-goat IgG serum, isolated by DEAE-cellulose chromatography with 0.01 M phosphate buffer, pH 8.0, was labelled with fluorescein isothiocyanate (FITC) using the method of Wood et al. (1965) with slight modifications. FITC was added to the IgG solution (1% w/v), which had been adjusted to pH 9.1 with 0.5 M carbonate buffer at 4 ° C, and the mixture was maintained with stirring at 4 ° C for 6 h. The unconjugated FITC was removed by gel filtration through a Sephadex G-25 column and the FITC-antibody conjugates were fractionated by DEAE-cellulose chromatography using stepwise elution with 0.01 M, 0.05 M, 0.1 M, and 0.1 M phosphate buffer, pH 8.0; the last buffer contained 2 M NaC1. The fluorescein to protein molar ratio of the conjugated antibody was determined spectrophotometrically. The fraction of FITC-antibody conjugates with a fluorescein to protein ratio of 1.0 was used for the experiments.
Fluorescent Staining. The fresh tumor tissue was cut into blocks of about 125 mm 3 which were immediately frozen in hexane cooled to --78 ° C with the aid of a dry ice-acetone bath; after I0 min the frozen tissue were transferred into tightly capped vials and stored in a freezer at -7 0 ° C.
Several 4 ~ thick serial sections were sliced off the frozen tissue in a cryostat at --20 ° C, dried on microscope slides at room temperature, f'Lxed for 10 rain in cold acetone, and rinsed in cold PBS, pH 7.2, for 5 min. The tissue sections were then treated with the purified goat AGFA preparation (concentration: 1 mg/ml) at room temperature in a humid chamber for 45 rain. The slides were washed at least three times with cold PBS, and then treated with FITClabelled rabbit anti-goat IgG (concentration: 1 mg/ml) for 45 min at room temperature. The slides were finally rinsed again with cold PBS, mounted in buffered glycerol and examined under a Zeiss fluorescence microscope.
Two control slides were also included in this test, i.e., (1) without the addition of the goat AGFA, and (2) substitution of normal goat IgG for the goat AGFA in the first step of this 'sandwich' technique.
Immunoelectrophoresis. Immunoelectrophoresis was carried out according to the micromethod of Scheidegger (1955) in 0.85% agar in barbital buffer, pH 8.2, ionic strength 0.05.
In vivo Localization of 131I-labelled AGFA in the MC-D Sarcoma.
Since the immunotherapeutic protocols underlying the proposed models require the in vivo fixation of AGFA on the fibrin lattice in the tumor tissues, localization of these antibodies when administered in vivo was examined. For this purpose the MC-D tumor-bearing guinea pigs were divided into three groups, consisting of three guinea pigs per group. One group of guinea pigs served as controls and were injected i.v. with 20 ~g N of 131I-labelled normal goat IgG. The remaining two groups of guinea pigs were injected with the same amount of either 131I-labelled rabbit AGFA or 13q-labelled goat AGFA. 24--48 h after injection of radioactive antibodies, or normal IgG, 2 ml of blood was collected from each animal by heart puncture, and each animal was then given 500 units of heparin. The animals were then killed gradually by extensive perfusion with 500 ml of PBS containing 500 units of heparin by cannulation of vena cava caudalis.
Whole tumor tissue, lungs, heart, liver, spleen and kidneys were excised from the perfused animals. Each tissue was weighed and the radioactivity per gram of tissue and per milliliter of blood was determined in a well-type F-ray counter (Nuclear, Chicago). The total volume of blood was estimated as 8% of the weight of the animal. The percentage of the radioactive antibodies localized in each tissue was calculated using the expression: cpm/g x organ weight --background (cpm) X 100. Total cpm injected --background (cpm) anti-guinea pig fibrinogen antibodies bound labelled fibrinogen, whereas the goat A G F A , which was isolated with the aid of fibrin used as an imrnunosorbent and further depleted of any antibodies to fibrinogen by passage through the fibrinogen-Sepharose immunosorbent, showed no significant binding activity toward fibrinogen. This, and the previous experiments, clearly demonstrate the immunochemical purity of the antifibrin antibodies prepared in this study, i.e., these antibodies reacted uniquely with the specific antigenic determinants of fibrin.
Results
Specificity
In vitro Binding of A GFA to Fibrin. Figure 3 shows the binding curves of the purified 131I-labelled A G F A to fibrin and to the tumor tissue pellet (TTP). It is evident that the extent of binding of these antibodies to TTP was less than that to fibrin. Moreover, while the binding curve with fibrin reached a plateau at 70% of the radioactivity of the A G F A preparation, no plateau was reached with the TTP preparation at the same concentrations; this was not unexpected since TTP contained materials other than fibrin. On the other hand, 131I-labelled normal goat IgG showed no binding activity either to fibrin or to TTP, thus indicating that binding of the A G F A to fibrin or to TTP was immunologically specific. are reported here as percentages of the injected radioactivity dose found in the different tissues. From this graph, it can be clearly seen that AGFA was localized at a significantly higher level in the tumor tissue than in other organs, and that normal goat IgG was localized to only a small extent. Thus, these results indicate that the Cells. I 191 localization of AGFA in tumor tissue was specific and substantial (_~ 70% of injected dose). Moreover, it was shown that AGFA was localized primarily in the tumor nodules when these pure antibody preparations were injected in limiting amounts, i.e., 10 or 20 ~g N. Obviously, injection of AGFA in higher amounts resulted in the localization of a relatively lower fraction of these antibodies in the tumor foci. The difference, as observed in this graph, between rabbit and goat AGFA in their localization in the tumor tissue may reflect the different affinity of these two AGFA preparations.
In vivo Localization of AGFA in Tumor-
Immunofluorescent Staining of Fibrin in Tumor Tissue.
The localization of FITC-labelled rabbit anti-goat IgG antibodies illustrated in Figure 5 demonstrates the presence of a typical linear pattern of fibrin within the sarcoma tissue. On the other hand, treatment of an identical tumor section with only FITC-labelled rabbit anti-goat IgG antibodies (i.e., without prior treatment with goat AGFA) was completely devoid of fluorescence (figure not shown).
Discussion
As outlined in the Introduction, the hypothesis underlying the two proposed strategies for the destruction of tumor nodules is based on two mandatory conditions, i.e., (1) the fibrin matrix must exist in the tumor nodule, and (2) the administration of xenogeneic antifibrin antibodies into tumor-bearing animals must result in the predominant localization of these antibodies within the tumor site by fixation to the enmeshing fibrin matrix. The results of the in vitro experiments involving the The success of this investigation is a reflection of the efforts made to remove any traces of antibodies that have affinity for the guinea pig fibrinogen from the A G F A preparation. The results of immunoelectrophoresis and double antibody precipitation tests presented here convincingly demonstrate that the crossreacting antibodies to fibrinogen had been eliminated from the A G F A preparation. Since fibrin shares the major antigenic determinants of its precursor, i.e., the ubiquitous fibrinogen, most of the antibodies raised against either of these antigenic moieties will react with the other. The failure of earlier investigators (Day et al., 1959; Spar et al., 1964 ) to achieve high in vivo localization of antifibrin antibodies within a fibrin lattice may, therefore, be attributed to the presence of antibodies to fibrinogen in their preparation of antifibrin antibody. In an experiment not reported here, evidence has been obtained to show that the half-life of goat IgG in tumor-bearing guinea pigs was about 41/2 days. Therefore, had the crossreacting antifibrinogen antibodies not been removed from the antifibrin antibody preparation, most of the injected antibodies would have reacted with the fibrinogen in circulation leading to soluble antigen-antibody complexes in antigen excess, which might have remained in circulation for extended periods or been deposited in various tissues nonspecifically.
The fact that only 70% of the 131I-labelled goat A G F A preparation was bound to fibrin is interpreted as indicating that some of the antibodies had been denatured during the iodination procedure, and probably also on elution from the fibrin immunosorbent with glycine-HC1 buffer. It has been shown in another study in this laboratory (Kisil et al., 1974 ) that denaturation of antibodies occurs at low concentration, and particularly readily at the low pH used for their elution from the immunosorbent; this may be minimized by adding proteins such as serum albumin to act as stabilizers. Since, for testing in vivo the validity of the hypothesis underlying this study, it will not be necessary to label A G F A with a radioactive marker prior to injection into MC-D sarcoma-bearing guinea pigs, the extent of denaturation of these antibodies, if any, will be obviously less than 30%.
The important conclusion which can be derived from this study is that it is possible to prepare and isolate antibodies specific to the unique antigenic determinants of fibrin which are distinct from the antigenic determinants shared by fibrin and fibrinogen. A plausible explanation for the antigenic uniqueness of fibrin stems from a consideration of the chemical and physical differal.: Use of Antifibrin Antibodies for Destruction of Tumor Cells. I ences between it and fibrinogen. Thus, during conversion of fibrinogen to fibrin in the presence of thrombin, the fibrinopeptides A and B are split off and the resulting polymer, i.e., fibrin, obviously differs in its primary and tertiary structures from fibrinogen; this is also reflected in the difference in their solubilities, the fibrin being an insoluble matrix of long chain polymers.
The succeeding manuscripts describe the utilization of this A G F A preparation for testing the strategies proposed in the Introduction for the destruction of the MC-D tumor in vivo by an indirect, cell-mediated and immunologically specific reaction (Lee et al., 1978a) , or by conjugates of A G F A with daunomycin (Lee et al., 1978b) . Moreover, it is obvious that, in addition to their therapeutic potential, antifibrin antibodies may prove to be valuable diagnostic tools for localization of tumor foci associated with fibrin.
